[
    [
        {
            "time": "2021-10-27",
            "original_text": "复星医药前三季净利润同比增长43.8% 拟对外收购以丰富疫苗管线",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润",
                    "同比增长",
                    "疫苗管线"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药前三季净利润同比增长43.8% 拟对外收购以丰富疫苗管线",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "复星医药前三季净利润36亿同比增44%，半年4次出售资产回收资金41亿",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润",
                    "资产出售",
                    "资金回收"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药前三季净利润36亿同比增44%，半年4次出售资产回收资金41亿",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "浙商证券维持复星医药买入评级，复星医药2021Q3业绩点评：符合预期，看好H2业绩表现",
            "features": {
                "keywords": [
                    "浙商证券",
                    "买入评级",
                    "业绩点评",
                    "复星医药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙商证券维持复星医药买入评级，复星医药2021Q3业绩点评：符合预期，看好H2业绩表现",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "中泰证券维持复星医药买入评级：创新多点开花，新冠疫苗带来可观增量",
            "features": {
                "keywords": [
                    "中泰证券",
                    "买入评级",
                    "创新",
                    "新冠疫苗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持复星医药买入评级：创新多点开花，新冠疫苗带来可观增量",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "国金证券维持复星医药买入评级：新品种放量持续，创新技术推进在望",
            "features": {
                "keywords": [
                    "国金证券",
                    "买入评级",
                    "新品种",
                    "创新技术"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券维持复星医药买入评级：新品种放量持续，创新技术推进在望",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "复星医药：前三季实现净利润35.65亿元，同比增长43.8%",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润",
                    "同比增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：前三季实现净利润35.65亿元，同比增长43.8%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "港股通】复星医药(02196)拟斥近40亿元收疫苗研发生产公司73.01%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "疫苗研发",
                    "股权收购"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股通】复星医药(02196)拟斥近40亿元收疫苗研发生产公司73.01%股权",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "复星医药：以代价11.08亿收购目标公司32.52%的股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "股权收购",
                    "代价"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：以代价11.08亿收购目标公司32.52%的股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]